Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial
Lancet, Infect. dis.; 13 (4), 2013
In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with antituberculosis drugs. We aimed to compare efficacy and safety of a nevirapine-based antiretroviral therapy (started at full dose) with an ef...
AIDS-Related Opportunistic Infections/therapy, Anti-HIV Agents/administration & dosage, Anti-HIV Agents/therapeutic use, Anti-HIV Agents/radiation effects, Antitubercular Agents/therapeutic use, Benzoxazines/therapeutic use, Benzoxazines/administration & dosage, Benzoxazines/adverse effects, Coinfection, Cyclopropanes, Drug Interactions, Drug Therapy, Combination, HIV Infections/therapy, Nevirapine/therapeutic use, Nevirapine/adverse effects, Nevirapine/administration & dosage, Treatment Outcome, Tuberculosis/complications, Tuberculosis/therapy, Tuberculosis, Pulmonary/complications, Tuberculosis, Pulmonary/therapy, Mozambique/epidemiology